Julie Dubois

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

Arnon P. Kater, Jenny Wu, Thomas J. Kipps et al. · Journal of Clinical Oncology · 2020 · 209 citations · Full text

Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre

Mégane Jermini, Julie Dubois, Pierre‐Yves Rodondi et al. · Scientific Reports · 2019 · 121 citations · Full text

Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL

Marco V. Haselager, Karoline Kielbassa, Johanna ter Burg et al. · Blood · 2020 · 111 citations · Full text

Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment

Iris de Weerdt, Tom Hofland, Renate de Boer et al. · Blood Advances · 2019 · 105 citations · Full text

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

Arnon P. Kater, Mark‐David Levin, Julie Dubois et al. · The Lancet Oncology · 2022 · 55 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Medicine +10